Medical Care
Global Antisense Oligonucleotide (ASO) Therapeutics Market Research Report 2025
- Apr 07, 25
- ID: 167603
- Pages: 71
- Figures: 75
- Views: 31
The global market for Antisense Oligonucleotide (ASO) Therapeutics was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
North American market for Antisense Oligonucleotide (ASO) Therapeutics is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Antisense Oligonucleotide (ASO) Therapeutics is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The global market for Antisense Oligonucleotide (ASO) Therapeutics in Genetic Disorders is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Antisense Oligonucleotide (ASO) Therapeutics include Ionis Pharmaceuticals, Inc, Sarpeta Therapeutics Inc., Biogen Inc, Alnylam Pharmaceuticals, Inc, Antisense Therapeutics Limited, Arrowhead Pharmaceuticals Inc., Enzon Pharmaceuticals, Inc., Bio-Path Holdings, Inc., GlaxoSmithKline PLC, Geron Corporation (Geron), etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Antisense Oligonucleotide (ASO) Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Antisense Oligonucleotide (ASO) Therapeutics.
The Antisense Oligonucleotide (ASO) Therapeutics market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Antisense Oligonucleotide (ASO) Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Antisense Oligonucleotide (ASO) Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Ionis Pharmaceuticals, Inc
Sarpeta Therapeutics Inc.
Biogen Inc
Alnylam Pharmaceuticals, Inc
Antisense Therapeutics Limited
Arrowhead Pharmaceuticals Inc.
Enzon Pharmaceuticals, Inc.
Bio-Path Holdings, Inc.
GlaxoSmithKline PLC
Geron Corporation (Geron)
Segment by Type
Pulmonary Delivery
Intravenous Injections
Intradermal Injections
Intraperitoneal Injections
Topical Delivery
Others
Segment by Application
Genetic Disorders
Neurological Disorders
Oncological Disorders
Metabolic Disorders
Ophthalmic Disorders
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Antisense Oligonucleotide (ASO) Therapeutics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
North American market for Antisense Oligonucleotide (ASO) Therapeutics is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Antisense Oligonucleotide (ASO) Therapeutics is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The global market for Antisense Oligonucleotide (ASO) Therapeutics in Genetic Disorders is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Antisense Oligonucleotide (ASO) Therapeutics include Ionis Pharmaceuticals, Inc, Sarpeta Therapeutics Inc., Biogen Inc, Alnylam Pharmaceuticals, Inc, Antisense Therapeutics Limited, Arrowhead Pharmaceuticals Inc., Enzon Pharmaceuticals, Inc., Bio-Path Holdings, Inc., GlaxoSmithKline PLC, Geron Corporation (Geron), etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Antisense Oligonucleotide (ASO) Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Antisense Oligonucleotide (ASO) Therapeutics.
The Antisense Oligonucleotide (ASO) Therapeutics market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Antisense Oligonucleotide (ASO) Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Antisense Oligonucleotide (ASO) Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Ionis Pharmaceuticals, Inc
Sarpeta Therapeutics Inc.
Biogen Inc
Alnylam Pharmaceuticals, Inc
Antisense Therapeutics Limited
Arrowhead Pharmaceuticals Inc.
Enzon Pharmaceuticals, Inc.
Bio-Path Holdings, Inc.
GlaxoSmithKline PLC
Geron Corporation (Geron)
Segment by Type
Pulmonary Delivery
Intravenous Injections
Intradermal Injections
Intraperitoneal Injections
Topical Delivery
Others
Segment by Application
Genetic Disorders
Neurological Disorders
Oncological Disorders
Metabolic Disorders
Ophthalmic Disorders
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Antisense Oligonucleotide (ASO) Therapeutics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Antisense Oligonucleotide (ASO) Therapeutics Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Pulmonary Delivery
1.2.3 Intravenous Injections
1.2.4 Intradermal Injections
1.2.5 Intraperitoneal Injections
1.2.6 Topical Delivery
1.2.7 Others
1.3 Market by Application
1.3.1 Global Antisense Oligonucleotide (ASO) Therapeutics Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Genetic Disorders
1.3.3 Neurological Disorders
1.3.4 Oncological Disorders
1.3.5 Metabolic Disorders
1.3.6 Ophthalmic Disorders
1.3.7 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Antisense Oligonucleotide (ASO) Therapeutics Market Perspective (2020-2031)
2.2 Global Antisense Oligonucleotide (ASO) Therapeutics Growth Trends by Region
2.2.1 Global Antisense Oligonucleotide (ASO) Therapeutics Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Antisense Oligonucleotide (ASO) Therapeutics Historic Market Size by Region (2020-2025)
2.2.3 Antisense Oligonucleotide (ASO) Therapeutics Forecasted Market Size by Region (2026-2031)
2.3 Antisense Oligonucleotide (ASO) Therapeutics Market Dynamics
2.3.1 Antisense Oligonucleotide (ASO) Therapeutics Industry Trends
2.3.2 Antisense Oligonucleotide (ASO) Therapeutics Market Drivers
2.3.3 Antisense Oligonucleotide (ASO) Therapeutics Market Challenges
2.3.4 Antisense Oligonucleotide (ASO) Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Antisense Oligonucleotide (ASO) Therapeutics Players by Revenue
3.1.1 Global Top Antisense Oligonucleotide (ASO) Therapeutics Players by Revenue (2020-2025)
3.1.2 Global Antisense Oligonucleotide (ASO) Therapeutics Revenue Market Share by Players (2020-2025)
3.2 Global Antisense Oligonucleotide (ASO) Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Antisense Oligonucleotide (ASO) Therapeutics Revenue
3.4 Global Antisense Oligonucleotide (ASO) Therapeutics Market Concentration Ratio
3.4.1 Global Antisense Oligonucleotide (ASO) Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Antisense Oligonucleotide (ASO) Therapeutics Revenue in 2024
3.5 Global Key Players of Antisense Oligonucleotide (ASO) Therapeutics Head office and Area Served
3.6 Global Key Players of Antisense Oligonucleotide (ASO) Therapeutics, Product and Application
3.7 Global Key Players of Antisense Oligonucleotide (ASO) Therapeutics, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Antisense Oligonucleotide (ASO) Therapeutics Breakdown Data by Type
4.1 Global Antisense Oligonucleotide (ASO) Therapeutics Historic Market Size by Type (2020-2025)
4.2 Global Antisense Oligonucleotide (ASO) Therapeutics Forecasted Market Size by Type (2026-2031)
5 Antisense Oligonucleotide (ASO) Therapeutics Breakdown Data by Application
5.1 Global Antisense Oligonucleotide (ASO) Therapeutics Historic Market Size by Application (2020-2025)
5.2 Global Antisense Oligonucleotide (ASO) Therapeutics Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Antisense Oligonucleotide (ASO) Therapeutics Market Size (2020-2031)
6.2 North America Antisense Oligonucleotide (ASO) Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Antisense Oligonucleotide (ASO) Therapeutics Market Size by Country (2020-2025)
6.4 North America Antisense Oligonucleotide (ASO) Therapeutics Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Antisense Oligonucleotide (ASO) Therapeutics Market Size (2020-2031)
7.2 Europe Antisense Oligonucleotide (ASO) Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Antisense Oligonucleotide (ASO) Therapeutics Market Size by Country (2020-2025)
7.4 Europe Antisense Oligonucleotide (ASO) Therapeutics Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Size (2020-2031)
8.2 Asia-Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Size by Region (2020-2025)
8.4 Asia-Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Size (2020-2031)
9.2 Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Size by Country (2020-2025)
9.4 Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Antisense Oligonucleotide (ASO) Therapeutics Market Size (2020-2031)
10.2 Middle East & Africa Antisense Oligonucleotide (ASO) Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Antisense Oligonucleotide (ASO) Therapeutics Market Size by Country (2020-2025)
10.4 Middle East & Africa Antisense Oligonucleotide (ASO) Therapeutics Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Ionis Pharmaceuticals, Inc
11.1.1 Ionis Pharmaceuticals, Inc Company Details
11.1.2 Ionis Pharmaceuticals, Inc Business Overview
11.1.3 Ionis Pharmaceuticals, Inc Antisense Oligonucleotide (ASO) Therapeutics Introduction
11.1.4 Ionis Pharmaceuticals, Inc Revenue in Antisense Oligonucleotide (ASO) Therapeutics Business (2020-2025)
11.1.5 Ionis Pharmaceuticals, Inc Recent Development
11.2 Sarpeta Therapeutics Inc.
11.2.1 Sarpeta Therapeutics Inc. Company Details
11.2.2 Sarpeta Therapeutics Inc. Business Overview
11.2.3 Sarpeta Therapeutics Inc. Antisense Oligonucleotide (ASO) Therapeutics Introduction
11.2.4 Sarpeta Therapeutics Inc. Revenue in Antisense Oligonucleotide (ASO) Therapeutics Business (2020-2025)
11.2.5 Sarpeta Therapeutics Inc. Recent Development
11.3 Biogen Inc
11.3.1 Biogen Inc Company Details
11.3.2 Biogen Inc Business Overview
11.3.3 Biogen Inc Antisense Oligonucleotide (ASO) Therapeutics Introduction
11.3.4 Biogen Inc Revenue in Antisense Oligonucleotide (ASO) Therapeutics Business (2020-2025)
11.3.5 Biogen Inc Recent Development
11.4 Alnylam Pharmaceuticals, Inc
11.4.1 Alnylam Pharmaceuticals, Inc Company Details
11.4.2 Alnylam Pharmaceuticals, Inc Business Overview
11.4.3 Alnylam Pharmaceuticals, Inc Antisense Oligonucleotide (ASO) Therapeutics Introduction
11.4.4 Alnylam Pharmaceuticals, Inc Revenue in Antisense Oligonucleotide (ASO) Therapeutics Business (2020-2025)
11.4.5 Alnylam Pharmaceuticals, Inc Recent Development
11.5 Antisense Therapeutics Limited
11.5.1 Antisense Therapeutics Limited Company Details
11.5.2 Antisense Therapeutics Limited Business Overview
11.5.3 Antisense Therapeutics Limited Antisense Oligonucleotide (ASO) Therapeutics Introduction
11.5.4 Antisense Therapeutics Limited Revenue in Antisense Oligonucleotide (ASO) Therapeutics Business (2020-2025)
11.5.5 Antisense Therapeutics Limited Recent Development
11.6 Arrowhead Pharmaceuticals Inc.
11.6.1 Arrowhead Pharmaceuticals Inc. Company Details
11.6.2 Arrowhead Pharmaceuticals Inc. Business Overview
11.6.3 Arrowhead Pharmaceuticals Inc. Antisense Oligonucleotide (ASO) Therapeutics Introduction
11.6.4 Arrowhead Pharmaceuticals Inc. Revenue in Antisense Oligonucleotide (ASO) Therapeutics Business (2020-2025)
11.6.5 Arrowhead Pharmaceuticals Inc. Recent Development
11.7 Enzon Pharmaceuticals, Inc.
11.7.1 Enzon Pharmaceuticals, Inc. Company Details
11.7.2 Enzon Pharmaceuticals, Inc. Business Overview
11.7.3 Enzon Pharmaceuticals, Inc. Antisense Oligonucleotide (ASO) Therapeutics Introduction
11.7.4 Enzon Pharmaceuticals, Inc. Revenue in Antisense Oligonucleotide (ASO) Therapeutics Business (2020-2025)
11.7.5 Enzon Pharmaceuticals, Inc. Recent Development
11.8 Bio-Path Holdings, Inc.
11.8.1 Bio-Path Holdings, Inc. Company Details
11.8.2 Bio-Path Holdings, Inc. Business Overview
11.8.3 Bio-Path Holdings, Inc. Antisense Oligonucleotide (ASO) Therapeutics Introduction
11.8.4 Bio-Path Holdings, Inc. Revenue in Antisense Oligonucleotide (ASO) Therapeutics Business (2020-2025)
11.8.5 Bio-Path Holdings, Inc. Recent Development
11.9 GlaxoSmithKline PLC
11.9.1 GlaxoSmithKline PLC Company Details
11.9.2 GlaxoSmithKline PLC Business Overview
11.9.3 GlaxoSmithKline PLC Antisense Oligonucleotide (ASO) Therapeutics Introduction
11.9.4 GlaxoSmithKline PLC Revenue in Antisense Oligonucleotide (ASO) Therapeutics Business (2020-2025)
11.9.5 GlaxoSmithKline PLC Recent Development
11.10 Geron Corporation (Geron)
11.10.1 Geron Corporation (Geron) Company Details
11.10.2 Geron Corporation (Geron) Business Overview
11.10.3 Geron Corporation (Geron) Antisense Oligonucleotide (ASO) Therapeutics Introduction
11.10.4 Geron Corporation (Geron) Revenue in Antisense Oligonucleotide (ASO) Therapeutics Business (2020-2025)
11.10.5 Geron Corporation (Geron) Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Antisense Oligonucleotide (ASO) Therapeutics Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Pulmonary Delivery
1.2.3 Intravenous Injections
1.2.4 Intradermal Injections
1.2.5 Intraperitoneal Injections
1.2.6 Topical Delivery
1.2.7 Others
1.3 Market by Application
1.3.1 Global Antisense Oligonucleotide (ASO) Therapeutics Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Genetic Disorders
1.3.3 Neurological Disorders
1.3.4 Oncological Disorders
1.3.5 Metabolic Disorders
1.3.6 Ophthalmic Disorders
1.3.7 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Antisense Oligonucleotide (ASO) Therapeutics Market Perspective (2020-2031)
2.2 Global Antisense Oligonucleotide (ASO) Therapeutics Growth Trends by Region
2.2.1 Global Antisense Oligonucleotide (ASO) Therapeutics Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Antisense Oligonucleotide (ASO) Therapeutics Historic Market Size by Region (2020-2025)
2.2.3 Antisense Oligonucleotide (ASO) Therapeutics Forecasted Market Size by Region (2026-2031)
2.3 Antisense Oligonucleotide (ASO) Therapeutics Market Dynamics
2.3.1 Antisense Oligonucleotide (ASO) Therapeutics Industry Trends
2.3.2 Antisense Oligonucleotide (ASO) Therapeutics Market Drivers
2.3.3 Antisense Oligonucleotide (ASO) Therapeutics Market Challenges
2.3.4 Antisense Oligonucleotide (ASO) Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Antisense Oligonucleotide (ASO) Therapeutics Players by Revenue
3.1.1 Global Top Antisense Oligonucleotide (ASO) Therapeutics Players by Revenue (2020-2025)
3.1.2 Global Antisense Oligonucleotide (ASO) Therapeutics Revenue Market Share by Players (2020-2025)
3.2 Global Antisense Oligonucleotide (ASO) Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Antisense Oligonucleotide (ASO) Therapeutics Revenue
3.4 Global Antisense Oligonucleotide (ASO) Therapeutics Market Concentration Ratio
3.4.1 Global Antisense Oligonucleotide (ASO) Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Antisense Oligonucleotide (ASO) Therapeutics Revenue in 2024
3.5 Global Key Players of Antisense Oligonucleotide (ASO) Therapeutics Head office and Area Served
3.6 Global Key Players of Antisense Oligonucleotide (ASO) Therapeutics, Product and Application
3.7 Global Key Players of Antisense Oligonucleotide (ASO) Therapeutics, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Antisense Oligonucleotide (ASO) Therapeutics Breakdown Data by Type
4.1 Global Antisense Oligonucleotide (ASO) Therapeutics Historic Market Size by Type (2020-2025)
4.2 Global Antisense Oligonucleotide (ASO) Therapeutics Forecasted Market Size by Type (2026-2031)
5 Antisense Oligonucleotide (ASO) Therapeutics Breakdown Data by Application
5.1 Global Antisense Oligonucleotide (ASO) Therapeutics Historic Market Size by Application (2020-2025)
5.2 Global Antisense Oligonucleotide (ASO) Therapeutics Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Antisense Oligonucleotide (ASO) Therapeutics Market Size (2020-2031)
6.2 North America Antisense Oligonucleotide (ASO) Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Antisense Oligonucleotide (ASO) Therapeutics Market Size by Country (2020-2025)
6.4 North America Antisense Oligonucleotide (ASO) Therapeutics Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Antisense Oligonucleotide (ASO) Therapeutics Market Size (2020-2031)
7.2 Europe Antisense Oligonucleotide (ASO) Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Antisense Oligonucleotide (ASO) Therapeutics Market Size by Country (2020-2025)
7.4 Europe Antisense Oligonucleotide (ASO) Therapeutics Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Size (2020-2031)
8.2 Asia-Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Size by Region (2020-2025)
8.4 Asia-Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Size (2020-2031)
9.2 Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Size by Country (2020-2025)
9.4 Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Antisense Oligonucleotide (ASO) Therapeutics Market Size (2020-2031)
10.2 Middle East & Africa Antisense Oligonucleotide (ASO) Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Antisense Oligonucleotide (ASO) Therapeutics Market Size by Country (2020-2025)
10.4 Middle East & Africa Antisense Oligonucleotide (ASO) Therapeutics Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Ionis Pharmaceuticals, Inc
11.1.1 Ionis Pharmaceuticals, Inc Company Details
11.1.2 Ionis Pharmaceuticals, Inc Business Overview
11.1.3 Ionis Pharmaceuticals, Inc Antisense Oligonucleotide (ASO) Therapeutics Introduction
11.1.4 Ionis Pharmaceuticals, Inc Revenue in Antisense Oligonucleotide (ASO) Therapeutics Business (2020-2025)
11.1.5 Ionis Pharmaceuticals, Inc Recent Development
11.2 Sarpeta Therapeutics Inc.
11.2.1 Sarpeta Therapeutics Inc. Company Details
11.2.2 Sarpeta Therapeutics Inc. Business Overview
11.2.3 Sarpeta Therapeutics Inc. Antisense Oligonucleotide (ASO) Therapeutics Introduction
11.2.4 Sarpeta Therapeutics Inc. Revenue in Antisense Oligonucleotide (ASO) Therapeutics Business (2020-2025)
11.2.5 Sarpeta Therapeutics Inc. Recent Development
11.3 Biogen Inc
11.3.1 Biogen Inc Company Details
11.3.2 Biogen Inc Business Overview
11.3.3 Biogen Inc Antisense Oligonucleotide (ASO) Therapeutics Introduction
11.3.4 Biogen Inc Revenue in Antisense Oligonucleotide (ASO) Therapeutics Business (2020-2025)
11.3.5 Biogen Inc Recent Development
11.4 Alnylam Pharmaceuticals, Inc
11.4.1 Alnylam Pharmaceuticals, Inc Company Details
11.4.2 Alnylam Pharmaceuticals, Inc Business Overview
11.4.3 Alnylam Pharmaceuticals, Inc Antisense Oligonucleotide (ASO) Therapeutics Introduction
11.4.4 Alnylam Pharmaceuticals, Inc Revenue in Antisense Oligonucleotide (ASO) Therapeutics Business (2020-2025)
11.4.5 Alnylam Pharmaceuticals, Inc Recent Development
11.5 Antisense Therapeutics Limited
11.5.1 Antisense Therapeutics Limited Company Details
11.5.2 Antisense Therapeutics Limited Business Overview
11.5.3 Antisense Therapeutics Limited Antisense Oligonucleotide (ASO) Therapeutics Introduction
11.5.4 Antisense Therapeutics Limited Revenue in Antisense Oligonucleotide (ASO) Therapeutics Business (2020-2025)
11.5.5 Antisense Therapeutics Limited Recent Development
11.6 Arrowhead Pharmaceuticals Inc.
11.6.1 Arrowhead Pharmaceuticals Inc. Company Details
11.6.2 Arrowhead Pharmaceuticals Inc. Business Overview
11.6.3 Arrowhead Pharmaceuticals Inc. Antisense Oligonucleotide (ASO) Therapeutics Introduction
11.6.4 Arrowhead Pharmaceuticals Inc. Revenue in Antisense Oligonucleotide (ASO) Therapeutics Business (2020-2025)
11.6.5 Arrowhead Pharmaceuticals Inc. Recent Development
11.7 Enzon Pharmaceuticals, Inc.
11.7.1 Enzon Pharmaceuticals, Inc. Company Details
11.7.2 Enzon Pharmaceuticals, Inc. Business Overview
11.7.3 Enzon Pharmaceuticals, Inc. Antisense Oligonucleotide (ASO) Therapeutics Introduction
11.7.4 Enzon Pharmaceuticals, Inc. Revenue in Antisense Oligonucleotide (ASO) Therapeutics Business (2020-2025)
11.7.5 Enzon Pharmaceuticals, Inc. Recent Development
11.8 Bio-Path Holdings, Inc.
11.8.1 Bio-Path Holdings, Inc. Company Details
11.8.2 Bio-Path Holdings, Inc. Business Overview
11.8.3 Bio-Path Holdings, Inc. Antisense Oligonucleotide (ASO) Therapeutics Introduction
11.8.4 Bio-Path Holdings, Inc. Revenue in Antisense Oligonucleotide (ASO) Therapeutics Business (2020-2025)
11.8.5 Bio-Path Holdings, Inc. Recent Development
11.9 GlaxoSmithKline PLC
11.9.1 GlaxoSmithKline PLC Company Details
11.9.2 GlaxoSmithKline PLC Business Overview
11.9.3 GlaxoSmithKline PLC Antisense Oligonucleotide (ASO) Therapeutics Introduction
11.9.4 GlaxoSmithKline PLC Revenue in Antisense Oligonucleotide (ASO) Therapeutics Business (2020-2025)
11.9.5 GlaxoSmithKline PLC Recent Development
11.10 Geron Corporation (Geron)
11.10.1 Geron Corporation (Geron) Company Details
11.10.2 Geron Corporation (Geron) Business Overview
11.10.3 Geron Corporation (Geron) Antisense Oligonucleotide (ASO) Therapeutics Introduction
11.10.4 Geron Corporation (Geron) Revenue in Antisense Oligonucleotide (ASO) Therapeutics Business (2020-2025)
11.10.5 Geron Corporation (Geron) Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Antisense Oligonucleotide (ASO) Therapeutics Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Pulmonary Delivery
Table 3. Key Players of Intravenous Injections
Table 4. Key Players of Intradermal Injections
Table 5. Key Players of Intraperitoneal Injections
Table 6. Key Players of Topical Delivery
Table 7. Key Players of Others
Table 8. Global Antisense Oligonucleotide (ASO) Therapeutics Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 9. Global Antisense Oligonucleotide (ASO) Therapeutics Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 10. Global Antisense Oligonucleotide (ASO) Therapeutics Market Size by Region (2020-2025) & (US$ Million)
Table 11. Global Antisense Oligonucleotide (ASO) Therapeutics Market Share by Region (2020-2025)
Table 12. Global Antisense Oligonucleotide (ASO) Therapeutics Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 13. Global Antisense Oligonucleotide (ASO) Therapeutics Market Share by Region (2026-2031)
Table 14. Antisense Oligonucleotide (ASO) Therapeutics Market Trends
Table 15. Antisense Oligonucleotide (ASO) Therapeutics Market Drivers
Table 16. Antisense Oligonucleotide (ASO) Therapeutics Market Challenges
Table 17. Antisense Oligonucleotide (ASO) Therapeutics Market Restraints
Table 18. Global Antisense Oligonucleotide (ASO) Therapeutics Revenue by Players (2020-2025) & (US$ Million)
Table 19. Global Antisense Oligonucleotide (ASO) Therapeutics Market Share by Players (2020-2025)
Table 20. Global Top Antisense Oligonucleotide (ASO) Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antisense Oligonucleotide (ASO) Therapeutics as of 2024)
Table 21. Ranking of Global Top Antisense Oligonucleotide (ASO) Therapeutics Companies by Revenue (US$ Million) in 2024
Table 22. Global 5 Largest Players Market Share by Antisense Oligonucleotide (ASO) Therapeutics Revenue (CR5 and HHI) & (2020-2025)
Table 23. Global Key Players of Antisense Oligonucleotide (ASO) Therapeutics, Headquarters and Area Served
Table 24. Global Key Players of Antisense Oligonucleotide (ASO) Therapeutics, Product and Application
Table 25. Global Key Players of Antisense Oligonucleotide (ASO) Therapeutics, Date of Enter into This Industry
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Antisense Oligonucleotide (ASO) Therapeutics Market Size by Type (2020-2025) & (US$ Million)
Table 28. Global Antisense Oligonucleotide (ASO) Therapeutics Revenue Market Share by Type (2020-2025)
Table 29. Global Antisense Oligonucleotide (ASO) Therapeutics Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 30. Global Antisense Oligonucleotide (ASO) Therapeutics Revenue Market Share by Type (2026-2031)
Table 31. Global Antisense Oligonucleotide (ASO) Therapeutics Market Size by Application (2020-2025) & (US$ Million)
Table 32. Global Antisense Oligonucleotide (ASO) Therapeutics Revenue Market Share by Application (2020-2025)
Table 33. Global Antisense Oligonucleotide (ASO) Therapeutics Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 34. Global Antisense Oligonucleotide (ASO) Therapeutics Revenue Market Share by Application (2026-2031)
Table 35. North America Antisense Oligonucleotide (ASO) Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 36. North America Antisense Oligonucleotide (ASO) Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 37. North America Antisense Oligonucleotide (ASO) Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 38. Europe Antisense Oligonucleotide (ASO) Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 39. Europe Antisense Oligonucleotide (ASO) Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 40. Europe Antisense Oligonucleotide (ASO) Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 41. Asia-Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 42. Asia-Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Size by Region (2020-2025) & (US$ Million)
Table 43. Asia-Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Size by Region (2026-2031) & (US$ Million)
Table 44. Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 45. Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 46. Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 47. Middle East & Africa Antisense Oligonucleotide (ASO) Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 48. Middle East & Africa Antisense Oligonucleotide (ASO) Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 49. Middle East & Africa Antisense Oligonucleotide (ASO) Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 50. Ionis Pharmaceuticals, Inc Company Details
Table 51. Ionis Pharmaceuticals, Inc Business Overview
Table 52. Ionis Pharmaceuticals, Inc Antisense Oligonucleotide (ASO) Therapeutics Product
Table 53. Ionis Pharmaceuticals, Inc Revenue in Antisense Oligonucleotide (ASO) Therapeutics Business (2020-2025) & (US$ Million)
Table 54. Ionis Pharmaceuticals, Inc Recent Development
Table 55. Sarpeta Therapeutics Inc. Company Details
Table 56. Sarpeta Therapeutics Inc. Business Overview
Table 57. Sarpeta Therapeutics Inc. Antisense Oligonucleotide (ASO) Therapeutics Product
Table 58. Sarpeta Therapeutics Inc. Revenue in Antisense Oligonucleotide (ASO) Therapeutics Business (2020-2025) & (US$ Million)
Table 59. Sarpeta Therapeutics Inc. Recent Development
Table 60. Biogen Inc Company Details
Table 61. Biogen Inc Business Overview
Table 62. Biogen Inc Antisense Oligonucleotide (ASO) Therapeutics Product
Table 63. Biogen Inc Revenue in Antisense Oligonucleotide (ASO) Therapeutics Business (2020-2025) & (US$ Million)
Table 64. Biogen Inc Recent Development
Table 65. Alnylam Pharmaceuticals, Inc Company Details
Table 66. Alnylam Pharmaceuticals, Inc Business Overview
Table 67. Alnylam Pharmaceuticals, Inc Antisense Oligonucleotide (ASO) Therapeutics Product
Table 68. Alnylam Pharmaceuticals, Inc Revenue in Antisense Oligonucleotide (ASO) Therapeutics Business (2020-2025) & (US$ Million)
Table 69. Alnylam Pharmaceuticals, Inc Recent Development
Table 70. Antisense Therapeutics Limited Company Details
Table 71. Antisense Therapeutics Limited Business Overview
Table 72. Antisense Therapeutics Limited Antisense Oligonucleotide (ASO) Therapeutics Product
Table 73. Antisense Therapeutics Limited Revenue in Antisense Oligonucleotide (ASO) Therapeutics Business (2020-2025) & (US$ Million)
Table 74. Antisense Therapeutics Limited Recent Development
Table 75. Arrowhead Pharmaceuticals Inc. Company Details
Table 76. Arrowhead Pharmaceuticals Inc. Business Overview
Table 77. Arrowhead Pharmaceuticals Inc. Antisense Oligonucleotide (ASO) Therapeutics Product
Table 78. Arrowhead Pharmaceuticals Inc. Revenue in Antisense Oligonucleotide (ASO) Therapeutics Business (2020-2025) & (US$ Million)
Table 79. Arrowhead Pharmaceuticals Inc. Recent Development
Table 80. Enzon Pharmaceuticals, Inc. Company Details
Table 81. Enzon Pharmaceuticals, Inc. Business Overview
Table 82. Enzon Pharmaceuticals, Inc. Antisense Oligonucleotide (ASO) Therapeutics Product
Table 83. Enzon Pharmaceuticals, Inc. Revenue in Antisense Oligonucleotide (ASO) Therapeutics Business (2020-2025) & (US$ Million)
Table 84. Enzon Pharmaceuticals, Inc. Recent Development
Table 85. Bio-Path Holdings, Inc. Company Details
Table 86. Bio-Path Holdings, Inc. Business Overview
Table 87. Bio-Path Holdings, Inc. Antisense Oligonucleotide (ASO) Therapeutics Product
Table 88. Bio-Path Holdings, Inc. Revenue in Antisense Oligonucleotide (ASO) Therapeutics Business (2020-2025) & (US$ Million)
Table 89. Bio-Path Holdings, Inc. Recent Development
Table 90. GlaxoSmithKline PLC Company Details
Table 91. GlaxoSmithKline PLC Business Overview
Table 92. GlaxoSmithKline PLC Antisense Oligonucleotide (ASO) Therapeutics Product
Table 93. GlaxoSmithKline PLC Revenue in Antisense Oligonucleotide (ASO) Therapeutics Business (2020-2025) & (US$ Million)
Table 94. GlaxoSmithKline PLC Recent Development
Table 95. Geron Corporation (Geron) Company Details
Table 96. Geron Corporation (Geron) Business Overview
Table 97. Geron Corporation (Geron) Antisense Oligonucleotide (ASO) Therapeutics Product
Table 98. Geron Corporation (Geron) Revenue in Antisense Oligonucleotide (ASO) Therapeutics Business (2020-2025) & (US$ Million)
Table 99. Geron Corporation (Geron) Recent Development
Table 100. Research Programs/Design for This Report
Table 101. Key Data Information from Secondary Sources
Table 102. Key Data Information from Primary Sources
Table 103. Authors List of This Report
List of Figures
Figure 1. Antisense Oligonucleotide (ASO) Therapeutics Picture
Figure 2. Global Antisense Oligonucleotide (ASO) Therapeutics Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Antisense Oligonucleotide (ASO) Therapeutics Market Share by Type: 2024 VS 2031
Figure 4. Pulmonary Delivery Features
Figure 5. Intravenous Injections Features
Figure 6. Intradermal Injections Features
Figure 7. Intraperitoneal Injections Features
Figure 8. Topical Delivery Features
Figure 9. Others Features
Figure 10. Global Antisense Oligonucleotide (ASO) Therapeutics Market Size by Application (2020-2031) & (US$ Million)
Figure 11. Global Antisense Oligonucleotide (ASO) Therapeutics Market Share by Application: 2024 VS 2031
Figure 12. Genetic Disorders Case Studies
Figure 13. Neurological Disorders Case Studies
Figure 14. Oncological Disorders Case Studies
Figure 15. Metabolic Disorders Case Studies
Figure 16. Ophthalmic Disorders Case Studies
Figure 17. Others Case Studies
Figure 18. Antisense Oligonucleotide (ASO) Therapeutics Report Years Considered
Figure 19. Global Antisense Oligonucleotide (ASO) Therapeutics Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 20. Global Antisense Oligonucleotide (ASO) Therapeutics Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 21. Global Antisense Oligonucleotide (ASO) Therapeutics Market Share by Region: 2024 VS 2031
Figure 22. Global Antisense Oligonucleotide (ASO) Therapeutics Market Share by Players in 2024
Figure 23. Global Top Antisense Oligonucleotide (ASO) Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antisense Oligonucleotide (ASO) Therapeutics as of 2024)
Figure 24. The Top 10 and 5 Players Market Share by Antisense Oligonucleotide (ASO) Therapeutics Revenue in 2024
Figure 25. North America Antisense Oligonucleotide (ASO) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. North America Antisense Oligonucleotide (ASO) Therapeutics Market Share by Country (2020-2031)
Figure 27. United States Antisense Oligonucleotide (ASO) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. Canada Antisense Oligonucleotide (ASO) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Europe Antisense Oligonucleotide (ASO) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Europe Antisense Oligonucleotide (ASO) Therapeutics Market Share by Country (2020-2031)
Figure 31. Germany Antisense Oligonucleotide (ASO) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. France Antisense Oligonucleotide (ASO) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. U.K. Antisense Oligonucleotide (ASO) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Italy Antisense Oligonucleotide (ASO) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Russia Antisense Oligonucleotide (ASO) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. Nordic Countries Antisense Oligonucleotide (ASO) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Asia-Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Asia-Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Share by Region (2020-2031)
Figure 39. China Antisense Oligonucleotide (ASO) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Japan Antisense Oligonucleotide (ASO) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. South Korea Antisense Oligonucleotide (ASO) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Southeast Asia Antisense Oligonucleotide (ASO) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. India Antisense Oligonucleotide (ASO) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Australia Antisense Oligonucleotide (ASO) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Share by Country (2020-2031)
Figure 47. Mexico Antisense Oligonucleotide (ASO) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. Brazil Antisense Oligonucleotide (ASO) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. Middle East & Africa Antisense Oligonucleotide (ASO) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 50. Middle East & Africa Antisense Oligonucleotide (ASO) Therapeutics Market Share by Country (2020-2031)
Figure 51. Turkey Antisense Oligonucleotide (ASO) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 52. Saudi Arabia Antisense Oligonucleotide (ASO) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 53. UAE Antisense Oligonucleotide (ASO) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 54. Ionis Pharmaceuticals, Inc Revenue Growth Rate in Antisense Oligonucleotide (ASO) Therapeutics Business (2020-2025)
Figure 55. Sarpeta Therapeutics Inc. Revenue Growth Rate in Antisense Oligonucleotide (ASO) Therapeutics Business (2020-2025)
Figure 56. Biogen Inc Revenue Growth Rate in Antisense Oligonucleotide (ASO) Therapeutics Business (2020-2025)
Figure 57. Alnylam Pharmaceuticals, Inc Revenue Growth Rate in Antisense Oligonucleotide (ASO) Therapeutics Business (2020-2025)
Figure 58. Antisense Therapeutics Limited Revenue Growth Rate in Antisense Oligonucleotide (ASO) Therapeutics Business (2020-2025)
Figure 59. Arrowhead Pharmaceuticals Inc. Revenue Growth Rate in Antisense Oligonucleotide (ASO) Therapeutics Business (2020-2025)
Figure 60. Enzon Pharmaceuticals, Inc. Revenue Growth Rate in Antisense Oligonucleotide (ASO) Therapeutics Business (2020-2025)
Figure 61. Bio-Path Holdings, Inc. Revenue Growth Rate in Antisense Oligonucleotide (ASO) Therapeutics Business (2020-2025)
Figure 62. GlaxoSmithKline PLC Revenue Growth Rate in Antisense Oligonucleotide (ASO) Therapeutics Business (2020-2025)
Figure 63. Geron Corporation (Geron) Revenue Growth Rate in Antisense Oligonucleotide (ASO) Therapeutics Business (2020-2025)
Figure 64. Bottom-up and Top-down Approaches for This Report
Figure 65. Data Triangulation
Figure 66. Key Executives Interviewed
Table 1. Global Antisense Oligonucleotide (ASO) Therapeutics Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Pulmonary Delivery
Table 3. Key Players of Intravenous Injections
Table 4. Key Players of Intradermal Injections
Table 5. Key Players of Intraperitoneal Injections
Table 6. Key Players of Topical Delivery
Table 7. Key Players of Others
Table 8. Global Antisense Oligonucleotide (ASO) Therapeutics Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 9. Global Antisense Oligonucleotide (ASO) Therapeutics Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 10. Global Antisense Oligonucleotide (ASO) Therapeutics Market Size by Region (2020-2025) & (US$ Million)
Table 11. Global Antisense Oligonucleotide (ASO) Therapeutics Market Share by Region (2020-2025)
Table 12. Global Antisense Oligonucleotide (ASO) Therapeutics Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 13. Global Antisense Oligonucleotide (ASO) Therapeutics Market Share by Region (2026-2031)
Table 14. Antisense Oligonucleotide (ASO) Therapeutics Market Trends
Table 15. Antisense Oligonucleotide (ASO) Therapeutics Market Drivers
Table 16. Antisense Oligonucleotide (ASO) Therapeutics Market Challenges
Table 17. Antisense Oligonucleotide (ASO) Therapeutics Market Restraints
Table 18. Global Antisense Oligonucleotide (ASO) Therapeutics Revenue by Players (2020-2025) & (US$ Million)
Table 19. Global Antisense Oligonucleotide (ASO) Therapeutics Market Share by Players (2020-2025)
Table 20. Global Top Antisense Oligonucleotide (ASO) Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antisense Oligonucleotide (ASO) Therapeutics as of 2024)
Table 21. Ranking of Global Top Antisense Oligonucleotide (ASO) Therapeutics Companies by Revenue (US$ Million) in 2024
Table 22. Global 5 Largest Players Market Share by Antisense Oligonucleotide (ASO) Therapeutics Revenue (CR5 and HHI) & (2020-2025)
Table 23. Global Key Players of Antisense Oligonucleotide (ASO) Therapeutics, Headquarters and Area Served
Table 24. Global Key Players of Antisense Oligonucleotide (ASO) Therapeutics, Product and Application
Table 25. Global Key Players of Antisense Oligonucleotide (ASO) Therapeutics, Date of Enter into This Industry
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Antisense Oligonucleotide (ASO) Therapeutics Market Size by Type (2020-2025) & (US$ Million)
Table 28. Global Antisense Oligonucleotide (ASO) Therapeutics Revenue Market Share by Type (2020-2025)
Table 29. Global Antisense Oligonucleotide (ASO) Therapeutics Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 30. Global Antisense Oligonucleotide (ASO) Therapeutics Revenue Market Share by Type (2026-2031)
Table 31. Global Antisense Oligonucleotide (ASO) Therapeutics Market Size by Application (2020-2025) & (US$ Million)
Table 32. Global Antisense Oligonucleotide (ASO) Therapeutics Revenue Market Share by Application (2020-2025)
Table 33. Global Antisense Oligonucleotide (ASO) Therapeutics Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 34. Global Antisense Oligonucleotide (ASO) Therapeutics Revenue Market Share by Application (2026-2031)
Table 35. North America Antisense Oligonucleotide (ASO) Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 36. North America Antisense Oligonucleotide (ASO) Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 37. North America Antisense Oligonucleotide (ASO) Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 38. Europe Antisense Oligonucleotide (ASO) Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 39. Europe Antisense Oligonucleotide (ASO) Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 40. Europe Antisense Oligonucleotide (ASO) Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 41. Asia-Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 42. Asia-Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Size by Region (2020-2025) & (US$ Million)
Table 43. Asia-Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Size by Region (2026-2031) & (US$ Million)
Table 44. Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 45. Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 46. Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 47. Middle East & Africa Antisense Oligonucleotide (ASO) Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 48. Middle East & Africa Antisense Oligonucleotide (ASO) Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 49. Middle East & Africa Antisense Oligonucleotide (ASO) Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 50. Ionis Pharmaceuticals, Inc Company Details
Table 51. Ionis Pharmaceuticals, Inc Business Overview
Table 52. Ionis Pharmaceuticals, Inc Antisense Oligonucleotide (ASO) Therapeutics Product
Table 53. Ionis Pharmaceuticals, Inc Revenue in Antisense Oligonucleotide (ASO) Therapeutics Business (2020-2025) & (US$ Million)
Table 54. Ionis Pharmaceuticals, Inc Recent Development
Table 55. Sarpeta Therapeutics Inc. Company Details
Table 56. Sarpeta Therapeutics Inc. Business Overview
Table 57. Sarpeta Therapeutics Inc. Antisense Oligonucleotide (ASO) Therapeutics Product
Table 58. Sarpeta Therapeutics Inc. Revenue in Antisense Oligonucleotide (ASO) Therapeutics Business (2020-2025) & (US$ Million)
Table 59. Sarpeta Therapeutics Inc. Recent Development
Table 60. Biogen Inc Company Details
Table 61. Biogen Inc Business Overview
Table 62. Biogen Inc Antisense Oligonucleotide (ASO) Therapeutics Product
Table 63. Biogen Inc Revenue in Antisense Oligonucleotide (ASO) Therapeutics Business (2020-2025) & (US$ Million)
Table 64. Biogen Inc Recent Development
Table 65. Alnylam Pharmaceuticals, Inc Company Details
Table 66. Alnylam Pharmaceuticals, Inc Business Overview
Table 67. Alnylam Pharmaceuticals, Inc Antisense Oligonucleotide (ASO) Therapeutics Product
Table 68. Alnylam Pharmaceuticals, Inc Revenue in Antisense Oligonucleotide (ASO) Therapeutics Business (2020-2025) & (US$ Million)
Table 69. Alnylam Pharmaceuticals, Inc Recent Development
Table 70. Antisense Therapeutics Limited Company Details
Table 71. Antisense Therapeutics Limited Business Overview
Table 72. Antisense Therapeutics Limited Antisense Oligonucleotide (ASO) Therapeutics Product
Table 73. Antisense Therapeutics Limited Revenue in Antisense Oligonucleotide (ASO) Therapeutics Business (2020-2025) & (US$ Million)
Table 74. Antisense Therapeutics Limited Recent Development
Table 75. Arrowhead Pharmaceuticals Inc. Company Details
Table 76. Arrowhead Pharmaceuticals Inc. Business Overview
Table 77. Arrowhead Pharmaceuticals Inc. Antisense Oligonucleotide (ASO) Therapeutics Product
Table 78. Arrowhead Pharmaceuticals Inc. Revenue in Antisense Oligonucleotide (ASO) Therapeutics Business (2020-2025) & (US$ Million)
Table 79. Arrowhead Pharmaceuticals Inc. Recent Development
Table 80. Enzon Pharmaceuticals, Inc. Company Details
Table 81. Enzon Pharmaceuticals, Inc. Business Overview
Table 82. Enzon Pharmaceuticals, Inc. Antisense Oligonucleotide (ASO) Therapeutics Product
Table 83. Enzon Pharmaceuticals, Inc. Revenue in Antisense Oligonucleotide (ASO) Therapeutics Business (2020-2025) & (US$ Million)
Table 84. Enzon Pharmaceuticals, Inc. Recent Development
Table 85. Bio-Path Holdings, Inc. Company Details
Table 86. Bio-Path Holdings, Inc. Business Overview
Table 87. Bio-Path Holdings, Inc. Antisense Oligonucleotide (ASO) Therapeutics Product
Table 88. Bio-Path Holdings, Inc. Revenue in Antisense Oligonucleotide (ASO) Therapeutics Business (2020-2025) & (US$ Million)
Table 89. Bio-Path Holdings, Inc. Recent Development
Table 90. GlaxoSmithKline PLC Company Details
Table 91. GlaxoSmithKline PLC Business Overview
Table 92. GlaxoSmithKline PLC Antisense Oligonucleotide (ASO) Therapeutics Product
Table 93. GlaxoSmithKline PLC Revenue in Antisense Oligonucleotide (ASO) Therapeutics Business (2020-2025) & (US$ Million)
Table 94. GlaxoSmithKline PLC Recent Development
Table 95. Geron Corporation (Geron) Company Details
Table 96. Geron Corporation (Geron) Business Overview
Table 97. Geron Corporation (Geron) Antisense Oligonucleotide (ASO) Therapeutics Product
Table 98. Geron Corporation (Geron) Revenue in Antisense Oligonucleotide (ASO) Therapeutics Business (2020-2025) & (US$ Million)
Table 99. Geron Corporation (Geron) Recent Development
Table 100. Research Programs/Design for This Report
Table 101. Key Data Information from Secondary Sources
Table 102. Key Data Information from Primary Sources
Table 103. Authors List of This Report
List of Figures
Figure 1. Antisense Oligonucleotide (ASO) Therapeutics Picture
Figure 2. Global Antisense Oligonucleotide (ASO) Therapeutics Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Antisense Oligonucleotide (ASO) Therapeutics Market Share by Type: 2024 VS 2031
Figure 4. Pulmonary Delivery Features
Figure 5. Intravenous Injections Features
Figure 6. Intradermal Injections Features
Figure 7. Intraperitoneal Injections Features
Figure 8. Topical Delivery Features
Figure 9. Others Features
Figure 10. Global Antisense Oligonucleotide (ASO) Therapeutics Market Size by Application (2020-2031) & (US$ Million)
Figure 11. Global Antisense Oligonucleotide (ASO) Therapeutics Market Share by Application: 2024 VS 2031
Figure 12. Genetic Disorders Case Studies
Figure 13. Neurological Disorders Case Studies
Figure 14. Oncological Disorders Case Studies
Figure 15. Metabolic Disorders Case Studies
Figure 16. Ophthalmic Disorders Case Studies
Figure 17. Others Case Studies
Figure 18. Antisense Oligonucleotide (ASO) Therapeutics Report Years Considered
Figure 19. Global Antisense Oligonucleotide (ASO) Therapeutics Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 20. Global Antisense Oligonucleotide (ASO) Therapeutics Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 21. Global Antisense Oligonucleotide (ASO) Therapeutics Market Share by Region: 2024 VS 2031
Figure 22. Global Antisense Oligonucleotide (ASO) Therapeutics Market Share by Players in 2024
Figure 23. Global Top Antisense Oligonucleotide (ASO) Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antisense Oligonucleotide (ASO) Therapeutics as of 2024)
Figure 24. The Top 10 and 5 Players Market Share by Antisense Oligonucleotide (ASO) Therapeutics Revenue in 2024
Figure 25. North America Antisense Oligonucleotide (ASO) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. North America Antisense Oligonucleotide (ASO) Therapeutics Market Share by Country (2020-2031)
Figure 27. United States Antisense Oligonucleotide (ASO) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. Canada Antisense Oligonucleotide (ASO) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Europe Antisense Oligonucleotide (ASO) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Europe Antisense Oligonucleotide (ASO) Therapeutics Market Share by Country (2020-2031)
Figure 31. Germany Antisense Oligonucleotide (ASO) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. France Antisense Oligonucleotide (ASO) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. U.K. Antisense Oligonucleotide (ASO) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Italy Antisense Oligonucleotide (ASO) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Russia Antisense Oligonucleotide (ASO) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. Nordic Countries Antisense Oligonucleotide (ASO) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Asia-Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Asia-Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Share by Region (2020-2031)
Figure 39. China Antisense Oligonucleotide (ASO) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Japan Antisense Oligonucleotide (ASO) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. South Korea Antisense Oligonucleotide (ASO) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Southeast Asia Antisense Oligonucleotide (ASO) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. India Antisense Oligonucleotide (ASO) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Australia Antisense Oligonucleotide (ASO) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Share by Country (2020-2031)
Figure 47. Mexico Antisense Oligonucleotide (ASO) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. Brazil Antisense Oligonucleotide (ASO) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. Middle East & Africa Antisense Oligonucleotide (ASO) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 50. Middle East & Africa Antisense Oligonucleotide (ASO) Therapeutics Market Share by Country (2020-2031)
Figure 51. Turkey Antisense Oligonucleotide (ASO) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 52. Saudi Arabia Antisense Oligonucleotide (ASO) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 53. UAE Antisense Oligonucleotide (ASO) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 54. Ionis Pharmaceuticals, Inc Revenue Growth Rate in Antisense Oligonucleotide (ASO) Therapeutics Business (2020-2025)
Figure 55. Sarpeta Therapeutics Inc. Revenue Growth Rate in Antisense Oligonucleotide (ASO) Therapeutics Business (2020-2025)
Figure 56. Biogen Inc Revenue Growth Rate in Antisense Oligonucleotide (ASO) Therapeutics Business (2020-2025)
Figure 57. Alnylam Pharmaceuticals, Inc Revenue Growth Rate in Antisense Oligonucleotide (ASO) Therapeutics Business (2020-2025)
Figure 58. Antisense Therapeutics Limited Revenue Growth Rate in Antisense Oligonucleotide (ASO) Therapeutics Business (2020-2025)
Figure 59. Arrowhead Pharmaceuticals Inc. Revenue Growth Rate in Antisense Oligonucleotide (ASO) Therapeutics Business (2020-2025)
Figure 60. Enzon Pharmaceuticals, Inc. Revenue Growth Rate in Antisense Oligonucleotide (ASO) Therapeutics Business (2020-2025)
Figure 61. Bio-Path Holdings, Inc. Revenue Growth Rate in Antisense Oligonucleotide (ASO) Therapeutics Business (2020-2025)
Figure 62. GlaxoSmithKline PLC Revenue Growth Rate in Antisense Oligonucleotide (ASO) Therapeutics Business (2020-2025)
Figure 63. Geron Corporation (Geron) Revenue Growth Rate in Antisense Oligonucleotide (ASO) Therapeutics Business (2020-2025)
Figure 64. Bottom-up and Top-down Approaches for This Report
Figure 65. Data Triangulation
Figure 66. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Oral Antianginal Drugs Market Outlook, In‑Depth Analysis & Forecast to 2031
Oct 21, 25
Global Polyester BCF Yarns Market Outlook, In‑Depth Analysis & Forecast to 2031
Oct 21, 25
Global Glass Mat Reinforced Thermoplastics (GMT) for Automotive Market Outlook, In‑Depth Analysis & Forecast to 2031
Oct 21, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232